Go PLR Content Marketing Curaçao

Thursday, 8 March 2012

Vibra-Tabs

Generic Name: doxycycline (Oral route)

dox-i-SYE-kleen

Commonly used brand name(s)

In the U.S.

Adoxa

Adoxa CK

Adoxa Pak

Adoxa TT

Alodox

Doryx

Monodox

Oracea

Periostat

Vibramycin Calcium

Vibramycin Hyclate

Vibramycin Monohydrate

Vibra-Tabs

Available Dosage Forms:

Tablet

Powder for Suspension

Capsule

Capsule, Extended Release

Tablet, Delayed Release

Capsule, Delayed Release

Syrup

Therapeutic Class: Antibiotic

Chemical Class: Tetracycline (class)

Uses For Vibra-Tabs

Doxycycline is used to treat bacterial infections in many different parts of the body. It is also used to treat pimples and abscesses (usually on the face) that are caused by rosacea, also known as acne rosacea or adult acne.

Doxycycline delayed-release tablets are also used to prevent malaria and treat anthrax infection after possible exposure and other problems as determined by your doctor.

Doxycycline belongs to the class of medicines known as tetracycline antibiotics. It works by killing bacteria or preventing their growth. However, this medicine will not work for colds, flu, or other virus infections.

This medicine is available only with your doctor's prescription.

Before Using Vibra-Tabs

In deciding to use a medicine, the risks of taking the medicine must be weighed against the good it will do. This is a decision you and your doctor will make. For this medicine, the following should be considered:

Allergies

Tell your doctor if you have ever had any unusual or allergic reaction to this medicine or any other medicines. Also tell your health care professional if you have any other types of allergies, such as to foods, dyes, preservatives, or animals. For non-prescription products, read the label or package ingredients carefully.

Pediatric

Doxycycline may cause permanent discoloration of the teeth and slow down the growth of bones. This medicine should not be given to children 8 years of age and younger (except for treatment of exposure to inhalational anthrax), unless directed by the child's doctor.

Geriatric

Appropriate studies performed to date have not demonstrated geriatric-specific problems that would limit the usefulness of doxycycline in the elderly. However, elderly patients are more likely to have kidney, liver, or heart problems which may require caution and an adjustment in the dose for patients receiving doxycycline.

Pregnancy

	Pregnancy Category	Explanation
All Trimesters	D	Studies in pregnant women have demonstrated a risk to the fetus. However, the benefits of therapy in a life threatening situation or a serious disease, may outweigh the potential risk.

Breast Feeding

There are no adequate studies in women for determining infant risk when using this medication during breastfeeding. Weigh the potential benefits against the potential risks before taking this medication while breastfeeding.

Interactions with Medicines

Although certain medicines should not be used together at all, in other cases two different medicines may be used together even if an interaction might occur. In these cases, your doctor may want to change the dose, or other precautions may be necessary. When you are taking this medicine, it is especially important that your healthcare professional know if you are taking any of the medicines listed below. The following interactions have been selected on the basis of their potential significance and are not necessarily all-inclusive.

Using this medicine with any of the following medicines is not recommended. Your doctor may decide not to treat you with this medication or change some of the other medicines you take.

Acitretin

Using this medicine with any of the following medicines is usually not recommended, but may be required in some cases. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Digoxin

Isotretinoin

Methotrexate

Using this medicine with any of the following medicines may cause an increased risk of certain side effects, but using both drugs may be the best treatment for you. If both medicines are prescribed together, your doctor may change the dose or how often you use one or both of the medicines.

Aluminum Carbonate, Basic

Aluminum Hydroxide

Aluminum Phosphate

Bismuth Subsalicylate

Calcium

Desogestrel

Dienogest

Dihydroxyaluminum Aminoacetate

Dihydroxyaluminum Sodium Carbonate

Drospirenone

Estradiol Cypionate

Estradiol Valerate

Ethinyl Estradiol

Ethynodiol Diacetate

Etonogestrel

Fosphenytoin

Iron

Levonorgestrel

Magaldrate

Magnesium Carbonate

Magnesium Hydroxide

Magnesium Oxide

Magnesium Trisilicate

Medroxyprogesterone Acetate

Mestranol

Norelgestromin

Norethindrone

Norgestimate

Norgestrel

Penicillin G

Penicillin G Procaine

Penicillin V

Rifampin

Rifapentine

Interactions with Food/Tobacco/Alcohol

Certain medicines should not be used at or around the time of eating food or eating certain types of food since interactions may occur. Using alcohol or tobacco with certain medicines may also cause interactions to occur. Discuss with your healthcare professional the use of your medicine with food, alcohol, or tobacco.

Proper Use of doxycycline

This section provides information on the proper use of a number of products that contain doxycycline. It may not be specific to Vibra-Tabs. Please read with care.

Take this medicine exactly as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. To do so may increase the chance of side effects.

To help clear up your infection completely, keep taking this medicine for the full time of treatment, even if you begin to feel better after a few days. If you stop taking this medicine too soon, your symptoms may return.

If you are using Doryx® delayed-release tablets:

It may be taken with food or milk, if it upsets your stomach.

You may take this medicine by breaking the tablets. Hold the tablet between your thumb and index fingers close to the appropriate score (separation) line. Then, apply enough pressure to snap the tablet segments apart. Do not use the tablet if it does not break on the scored lines.

You may also take this medicine by sprinkling the equally broken tablets onto cold, soft food such as an applesauce. This mixture must be swallowed immediately without chewing and followed with a glass of cool water to ensure complete swallowing of the pellets. Do not store the mixture for later use.

Drink plenty of fluids to avoid throat irritation and ulceration.

If you are using this medicine to prevent malaria while traveling, start taking the medicine 1 or 2 days before you travel. Take the medicine every day during your trip and continue taking it for 4 weeks after you return. However, do not use the medicine for longer than 4 months.

If you are using For Oracea™ delayed-release capsules:

You should take this medicine on an empty stomach, preferably at least 1 hour before or 2 hours after meals.

You should take this medicine with a full glass of water while sitting or standing.

To prevent throat irritation, do not lay down right after taking this medicine.

Use only the brand of this medicine that your doctor prescribed. Different brands may not work the same way.

Dosing

The dose of this medicine will be different for different patients. Follow your doctor's orders or the directions on the label. The following information includes only the average doses of this medicine. If your dose is different, do not change it unless your doctor tells you to do so.

The amount of medicine that you take depends on the strength of the medicine. Also, the number of doses you take each day, the time allowed between doses, and the length of time you take the medicine depend on the medical problem for which you are using the medicine.

For oral dosage form (delayed-release tablets):
- For infections:
  - Adults—100 milligrams (mg) every 12 hours on the first day, then 100 mg once a day or 50 to 100 mg every 12 hours.
  - Children older than 8 years of age who weigh 45 kg or less—Dose is based on body weight and must be determined by your doctor. The dose is usually 4.4 milligrams (mg) per kilogram (kg) of body weight per day and divided into two doses on the first day of treatment. This is followed by 2.2 mg per kg of body weight per day, taken as a single dose or divided into two doses on the following days.
  - Children up to 8 years of age—Use is not recommended.
- For the prevention of malaria:
  - Adults—100 milligrams (mg) once a day. You should take the first dose one or two days before travel to an area where malaria may occur, and continue taking the medicine every day throughout travel and for 4 weeks after you leave the malarious area.
  - Children older than 8 years of age—Dose is based on body weight and must be determined by your doctor. The dose is usually 2 milligrams (mg) per kilogram (kg) of body weight per day, taken as a single dose. You should take the first dose one or two days before travel to an area where malaria may occur, and continue taking the medicine every day throughout travel and for 4 weeks after you leave the malarious area.
  - Children up to 8 years of age—Use is not recommended.

For oral dosage form (delayed-release capsules):
- For the treatment of pimples from rosacea:
  - Adults—40 milligrams (mg) or one capsule once a day, in the morning.
  - Children—Use and dose must be determined by your doctor.

Missed Dose

If you miss a dose of this medicine, take it as soon as possible. However, if it is almost time for your next dose, skip the missed dose and go back to your regular dosing schedule. Do not double doses.

Storage

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light. Keep from freezing.

Keep out of the reach of children.

Do not keep outdated medicine or medicine no longer needed.

Ask your healthcare professional how you should dispose of any medicine you do not use.

Precautions While Using Vibra-Tabs

If your symptoms do not improve within a few days, or if they become worse, check with your doctor.

Using this medicine while you are pregnant can harm your unborn baby. Use an effective form of birth control to keep from getting pregnant. If you think you have become pregnant while using this medicine, tell your doctor right away.

This medicine may darken the color of your skin, nails, eyes, teeth, gums, or scars. Talk with your doctor if you have any concerns.

Doxycycline may cause diarrhea, and in some cases it can be severe. It may occur 2 months or more after you stop taking this medicine. Do not take any medicine to treat diarrhea without first checking with your doctor. Diarrhea medicines may make the diarrhea worse or make it last longer. If you have any questions about this or if mild diarrhea continues or gets worse, check with your doctor.

Birth control pills (containing estrogen) may not work properly while you are using doxycycline. To keep from getting pregnant, use other forms of birth control. These include condoms, diaphragms, or contraceptive foams or jellies.

Doxycycline may cause your skin to be more sensitive to sunlight than it is normally. Exposure to sunlight, even for brief periods of time, may cause a skin rash, itching, redness or other discoloration of the skin, or a severe sunburn. When you begin taking this medicine:

Stay out of direct sunlight, especially between the hours of 10:00 a.m. and 3:00 p.m., if possible.

Wear protective clothing, including a hat. Also, wear sunglasses.

Apply a sunblock product that has a skin protection factor (SPF) number of at least 15. Some patients may require a product with a higher SPF number, especially if they have a fair complexion. If you have any questions about this, check with your doctor.

Apply a sunblock lipstick that has an SPF of at least 15 to protect your lips.

Do not use a sun lamp or tanning bed or booth.

If you have a severe reaction from the sun, check with your doctor.

Contact your doctor immediately if fever, rash, joint pain, or tiredness occurs. These could be symptoms of an autoimmune syndrome where the body attacks itself.

You should not take antacids that contain aluminum, calcium or magnesium, or any product that contains iron such as vitamin or mineral supplements.

If you are using this medicine to prevent malaria, take extra care not to get bitten by mosquitoes. Use protective clothing, mosquito netting or screens, and an insect repellent.

Before you have any medical tests, tell the medical doctor in charge that you are taking this medicine. The results of some tests may be affected by this medicine.

Do not take other medicines unless they have been discussed with your doctor. This includes prescription or nonprescription (over-the-counter [OTC]) medicines and herbal or vitamin supplements.

Vibra-Tabs Side Effects

Along with its needed effects, a medicine may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur:

Incidence not known

Abdominal or stomach tenderness

bloating

clay-colored stools

cough

dark urine

decreased appetite

diarrhea

diarrhea, watery and severe, which may also be bloody

difficulty with swallowing

dizziness

fast heartbeat

feeling of discomfort

fever

headache

hives, itching, puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue

hives or welts

increased thirst

inflammation of the joints

itching

joint or muscle pain

large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs

loss of appetite

nausea and vomiting

numbness or tingling of the face, hands, or feet

pain

rash

redness and soreness of the eyes

redness of the skin

shortness of breath

sore throat

sores in the mouth

stomach cramps

stomach pain or tenderness

swelling of the feet or lower legs

swollen lymph glands

tightness in the chest

unusual tiredness or weakness

unusual weight loss

wheezing

yellow eyes or skin

Some side effects may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

Incidence not known

Back, leg, or stomach pains

black, tarry stools

bleeding gums

blood in the urine or stools

blurred vision

bulging soft spot on the head of an infant

change in the ability to see colors, especially blue or yellow

chest pain, discomfort, or burning

chills

cracks in the skin

decrease in vision

difficulty breathing

discoloration of the thyroid glands

double vision

general body swelling

heartburn

increased sensitivity of the skin to sunlight

loss of heat from the body

lower back or side pain

nosebleeds

pain or burning in the throat

pain with swallowing

painful or difficult urination

pale skin

pinpoint red spots on the skin

rash with flat lesions or small raised lesions on the skin

red, swollen skin

redness or other discoloration of the skin

redness, swelling, or soreness of the tongue

scaly skin

severe nausea

severe stomach pain

severe sunburn

sores, ulcers, or white spots on the lips or tongue or inside the mouth

unusual bleeding or bruising

vomiting blood

Other side effects not listed may also occur in some patients. If you notice any other effects, check with your healthcare professional.

Call your doctor for medical advice about side effects. You may report side effects to the FDA at 1-800-FDA-1088.

See also: Vibra-Tabs side effects (in more detail)

The information contained in the Thomson Reuters Micromedex products as delivered by Drugs.com is intended as an educational aid only. It is not intended as medical advice for individual conditions or treatment. It is not a substitute for a medical exam, nor does it replace the need for services provided by medical professionals. Talk to your doctor, nurse or pharmacist before taking any prescription or over the counter drugs (including any herbal medicines or supplements) or following any treatment or regimen. Only your doctor, nurse, or pharmacist can provide you with advice on what is safe and effective for you.

The use of the Thomson Reuters Healthcare products is at your sole risk. These products are provided "AS IS" and "as available" for use, without warranties of any kind, either express or implied. Thomson Reuters Healthcare and Drugs.com make no representation or warranty as to the accuracy, reliability, timeliness, usefulness or completeness of any of the information contained in the products. Additionally, THOMSON REUTERS HEALTHCARE MAKES NO REPRESENTATION OR WARRANTIES AS TO THE OPINIONS OR OTHER SERVICE OR DATA YOU MAY ACCESS, DOWNLOAD OR USE AS A RESULT OF USE OF THE THOMSON REUTERS HEALTHCARE PRODUCTS. ALL IMPLIED WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE OR USE ARE HEREBY EXCLUDED. Thomson Reuters Healthcare does not assume any responsibility or risk for your use of the Thomson Reuters Healthcare products.

More Vibra-Tabs resources

Vibra-Tabs Side Effects (in more detail)
Vibra-Tabs Use in Pregnancy & Breastfeeding
Drug Images
Vibra-Tabs Drug Interactions
Vibra-Tabs Support Group
0 Reviews for Vibra-Tabs - Add your own review/rating

Vibra-Tabs MedFacts Consumer Leaflet (Wolters Kluwer)

Doxycycline Monograph (AHFS DI)

Doxycycline Professional Patient Advice (Wolters Kluwer)

Doxycycline Prescribing Information (FDA)

Doxycycline MedFacts Consumer Leaflet (Wolters Kluwer)

Adoxa MedFacts Consumer Leaflet (Wolters Kluwer)

Alodox Prescribing Information (FDA)

Doryx Delayed-Release Capsules MedFacts Consumer Leaflet (Wolters Kluwer)

Doryx Prescribing Information (FDA)

Doxycycline Calcium Monograph (AHFS DI)

Monodox Prescribing Information (FDA)

Ocudox Convenience Kit MedFacts Consumer Leaflet (Wolters Kluwer)

Oracea Prescribing Information (FDA)

Oracea Consumer Overview

Periostat MedFacts Consumer Leaflet (Wolters Kluwer)

Periostat Prescribing Information (FDA)

Vibramycin Prescribing Information (FDA)

Compare Vibra-Tabs with other medications

Acne
Actinomycosis
Amebiasis
Anthrax
Anthrax Prophylaxis
Bacterial Infection
Bartonellosis
Bronchitis
Brucellosis
Bullous Pemphigoid
Chlamydia Infection
Cholera
Cutaneous Bacillus anthracis
Ehrlichiosis
Enterocolitis
Epididymitis, Sexually Transmitted
Gastroenteritis
Granuloma Inguinale
Inclusion Conjunctivitis
Lyme Disease
Lyme Disease, Arthritis
Lyme Disease, Carditis
Lyme Disease, Erythema Chronicum Migrans
Lyme Disease, Neurologic
Lymphogranuloma Venereum
Malaria
Malaria Prevention
Melioidosis
Mycoplasma Pneumonia
Nongonococcal Urethritis
Ocular Rosacea
Ornithosis
Pelvic Inflammatory Disease
Pemphigoid
Pemphigus
Periodontitis
Plague
Pleural Effusion
Pneumonia
Proctitis
Prostatitis
Psittacosis
Rabbit Fever
Rickettsial Infection
Rosacea
Skin Infection
STD Prophylaxis
Syphilis, Early
Syphilis, Latent
Tertiary Syphilis
Trachoma
Upper Respiratory Tract Infection
Urinary Tract Infection

Monday, 5 March 2012

Acular eent

Generic Name: Ketorolac Tromethamine eent
Class: Nonsteroidal Anti-inflammatory Agents
ATC Class: S01BC05
VA Class: OP300
CAS Number: 74103-07-4

Introduction

Prototypical NSAIA; a pyrrolizine carboxylic acid derivative.¹ ² ³ ⁴ ¹⁴ ²¹ ²² ²⁵ ²⁶ ²⁷ ²⁸

Uses for Acular

Conjunctivitis

Temporary relief of ocular itching due to seasonal allergic (hay fever, pollinosis) conjunctivitis.¹ ¹⁴¹ ¹⁴² ¹⁴³

Postoperative Ocular Inflammation

Management of postoperative inflammation associated with cataract extraction.¹ ¹¹ ¹⁷ ¹⁸ ¹⁹ ⁶¹ ⁸⁵ ¹¹⁰ ¹⁴⁷

Postoperative Ocular Pain

Reduction of ocular pain and burning/stinging following corneal refractive surgery and photorefractive keratectomy (PRK).¹⁵⁵ ¹⁵⁶

Ketorolac tromethamine 0.5% preservative-free ophthalmic solution is used for the reduction of ocular pain and photophobia following incisional refractive surgery.¹⁵⁴

Cystoid Macular Edema

Treatment, with or without concomitant topical corticosteroid therapy, to prevent or relieve postoperative cystoid macular edema associated with cataract extraction†.⁶¹

Has been used for the active treatment of chronic aphakic or pseudophakic cystoid macular edema†.¹⁴ ²⁰ ²³

Inhibition of Intraoperative Miosis

Has been used prophylactically before ocular surgery to prevent or reduce intraoperative miosis†.⁵³ ⁸¹ ¹⁰⁶ ¹⁰⁷ ¹⁰⁸ ¹¹⁰ ¹³⁷ ¹³⁹

Acular Dosage and Administration

Administration

Ophthalmic Administration

Apply topically to the eye as an ophthalmic solution.¹ ¹⁵⁴ ¹⁵⁵

Avoid contamination of the solution container.¹⁵⁴

Do not administer while wearing contact lenses.¹ ¹⁵⁴ ¹⁵⁵

Preservative-free solution is for single use only in one or both eyes; use immediately after opening and discard any unused portion immediately after administration.¹⁵⁴

Has been safely administered with other ophthalmic medications (e.g., antibiotics, β-blockers, carbonic anhydrase inhibitors, cycloplegics, mydriatics).¹

Dosage

Available as ketorolac tromethamine; dosage expressed in terms of the salt.¹⁵⁴ ¹⁵⁵

Pediatric Patients

Conjunctivitis

Ophthalmic

Children ≥3 years of age: 1 drop (250 mg) of a 0.5% solution in the affected eye(s) 4 times daily.¹ ¹⁴¹ ¹⁴²

Postoperative Ocular Inflammation

Ophthalmic

Children ≥3 years of age: 1 drop (250 mcg) of a 0.5% solution in the eye(s) undergoing surgery 4 times daily beginning 24 hours after surgery and typically continuing for 2 weeks after surgery.¹

Postoperative Ocular Pain

Ophthalmic

Children ≥3 years of age undergoing ocular incisional refractive surgery: 1 drop (250 mcg) of a 0.5% preservative-free solution 4 times daily in the eye(s) that underwent surgery as needed for up to 3 days after surgery.¹⁵⁴

Children ≥3 years of age undergoing corneal refractive surgery: 1 drop (200 mcg) of a 0.4% solution 4 times daily in the eye(s) that underwent surgery as needed for up to 4 days after surgery.¹⁵⁵

Adults

Conjunctivitis

Ophthalmic

1 drop (250 mg) of a 0.5% solution in the affected eye(s) 4 times daily.¹ ¹⁴¹ ¹⁴²

Postoperative Ocular Inflammation

Ophthalmic

1 drop (250 mcg) of a 0.5% solution in the eye(s) undergoing surgery 4 times daily beginning 24 hours after surgery and typically continuing for 2 weeks after surgery.¹

Postoperative Ocular Pain

Ophthalmic

Patients undergoing ocular incisional refractive surgery: 1 drop (250 mcg) of a 0.5% preservative-free solution 4 times daily in the eye(s) that underwent surgery as needed for up to 3 days after surgery.¹⁵⁴

Patients undergoing corneal refractive surgery: 1 drop (200 mcg) of a 0.4% solution 4 times daily in the eye(s) that underwent surgery as needed for up to 4 days after surgery.¹⁵⁵

Cystoid Macular Edema

Postoperative Cystoid Macular Edema†

Ophthalmic

1–2 drops (250–500 mcg) of a 0.5% solution in the eye(s) undergoing surgery every 6–8 hours beginning 24 hours prior to surgery and continuing for 3–4 weeks after surgery.¹¹ ¹⁷ ¹⁸ ¹⁹ ⁶¹ ⁸⁵

Chronic Aphakic or Pseudophakic Cystoid Macular Edema†

Ophthalmic

1–2 drops (250–500 mcg) of a 0.5% solution in the affected eye(s) 4 times daily for 2–3 months.²⁰ ²³

Cautions for Acular

Contraindications

Known hypersensitivity to ketorolac tromethamine or any ingredient in the formulation.¹ ¹⁵⁴ ¹⁵⁵

Warnings/Precautions

Warnings

Hematologic Effects

May inhibit platelet aggregation and prolong bleeding time.¹ ¹³⁷ ¹⁵⁴ ¹⁵⁵

May increase bleeding (e.g., hyphemas) of ocular tissues in patients undergoing ocular surgery.¹ ²⁴ ⁵³ ¹⁰⁶ ¹⁵⁴ ¹⁵⁵

Use with caution in patients with underlying bleeding tendencies or in those receiving drugs known to prolong bleeding time.¹ ¹⁵⁴ ¹⁵⁵

Sensitivity Reactions

Cross-sensitivity

Possible cross-sensitivity with aspirin, phenylacetic acid derivatives, and other NSAIAs.¹ ¹⁵⁴ ¹⁵⁵ Use with caution in patients with history of hypersensitivity to these drugs.¹ ⁵⁴ ⁵⁵ ⁵⁶ ⁵⁷ ⁵⁸ ⁵⁹ ⁸⁵ ¹¹⁷ ¹¹⁸ ¹⁵⁴ ¹⁵⁵

General Precautions

Wound Healing Complications

Possible slow or delayed wound healing; may be potentiated with concomitant adminsitration of topical NSAIAs or topical corticosteroids.¹ ¹⁵⁴ ¹⁵⁵ (See Specific Drugs under Interactions.)

Ocular Effects

Use may result in keratitis.¹ ⁸⁵ ¹³⁹ ¹⁵⁴ ¹⁵⁵ In susceptible patients, continued use may result in epithelial breakdown, corneal thinning, erosion, ulceration, or perforation, which may be sight-threatening.¹ ¹⁵⁴ ¹⁵⁵

If manifestations of corneal epithelial breakdown occur, discontinue immediately and closely monitor corneal health.¹ ¹⁵⁴ ¹⁵⁵

Increased risk of sight-threatening, adverse corneal effects in patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, diabetes mellitus, ocular surface diseases (e.g., dry eye syndrome), rheumatoid arthritis, or repeat ocular surgeries within a short period of time; use with caution in such patients.¹ ¹⁵⁴ ¹⁵⁵

Use >24 hours prior to surgery or >14 days postoperatively may precipitate or exacerbate adverse corneal effects.¹ ¹⁵⁴ ¹⁵⁵

Specific Populations

Pregnancy

Category C.¹ ¹⁵⁴ ¹⁵⁵ Avoid use in the third trimester because of possible premature closure of the ductus arteriosus.¹ ¹⁵⁴ ¹⁵⁵

Lactation

Distributed into milk after systemic administration.² ¹⁴ ²¹ ²² ⁴⁸ ⁸⁵ Caution if used in nursing women.¹ ¹⁵⁴ ¹⁵⁵

Pediatric Use

Safety and efficacy not established in children <3 years of age.¹ ¹⁵⁴ ¹⁵⁵

Geriatric Use

No substantial differences in safety and efficacy relative to younger adults.¹ ¹⁵⁴ ¹⁵⁵

Common Adverse Effects

Ocular stinging and burning.¹ ¹⁵⁴ ¹⁵⁵

Interactions for Acular

No formal drug interaction studies to date.¹ ¹⁵⁴ ¹⁵⁵

Specific Drugs

Drug	Interaction	Comments
Corticosteroids, ophthalmic	Possible additive effects on delaying wound healing¹ ¹⁵⁴ ¹⁵⁵ Additive ocular anti-inflammatory activity¹ ¹⁵⁴ ¹⁵⁵	Concomitant use may increase the potential for wound healing complications¹ ¹⁵⁴ ¹⁵⁵ Potential for additive effects used to therapeutic advantage¹¹ ¹⁸ ⁸¹

Acular Pharmacokinetics

Absorption

Bioavailability

Extent of ocular and systemic absorption not fully elucidated;¹ however, limited concentrations are achieved systemically following topical application to the eye relative to usual oral or parenteral doses.¹ ¹⁴ ¹⁶ ¹⁸

Following topical application to the eye, plasma ketorolac concentrations were detectable (range: 10.7–22.5 ng/mL) in about 20% of patients.¹ ¹⁵⁴ ¹⁵⁵

Distribution

Extent

Distribution into human ocular tissues and fluids not fully characterized to date.¹ ¹⁴ ⁷⁸

Ketorolac crosses the placenta²¹ ²⁸ ⁴⁶ ⁴⁷ ⁷⁸ and is distributed into milk following systemic administration.² ¹⁴ ²¹ ²² ⁴⁸ ⁷⁸

Plasma Protein Binding

>99%.² ¹⁴ ²⁸ ⁴⁵ ⁴⁹ ⁷⁸

Stability

Storage

Ophthalmic

0.4% Solution

15–25°C.¹⁵⁵

0.5% Solution

Light-resistant containers at 15–30°C.¹ ¹⁵⁴

ActionsActions

Inhibits synthesis of certain ocular prostaglandins (e.g., PGE₂) in iris, ciliary body, and conjunctiva by inhibiting cyclooxygenase-1 (COX-1) and -2 (COX-2).¹ ² ⁴ ⁶ ¹⁰ ²¹ ²⁸ ⁴⁰ ⁶² ⁶⁶ ⁶⁸ ⁶⁹ ⁷⁰ ⁷¹ ⁷² ⁷³ ⁷⁷ ⁸⁰ ⁸¹ ¹¹⁰ ¹⁵⁴ ¹⁵⁵

Substantially reduces aqueous humor concentrations of these prostaglandins.¹ ⁸⁰ ⁸¹ ¹¹⁰ ¹²¹ ¹²² ¹²³ ¹²⁶ ¹²⁸

Does not appear to inhibit lipoxygenase;²¹ ⁸¹ does not inhibit aspects of inflammation mediated by leukotrienes.⁸¹ ¹¹⁹ ¹³⁷

Advice to Patients

Importance of learning and adhering to proper administration techniques to avoid contamination of the product.¹ ¹⁵⁴ ¹⁵⁵

Importance of removing contact lenses before administration.¹ ¹⁵⁴ ¹⁵⁵

Importance of women informing clinicians if they are or plan to become pregnant or plan to breast-feed.¹ ¹⁵⁴ ¹⁵⁵

Importance of informing clinicians of existing or contemplated concomitant therapy, including prescription and OTC drugs, as well as concomitant illnesses.¹ ¹⁵⁴ ¹⁵⁵

Importance of informing patients of other important precautionary information.¹ ¹⁵⁴ ¹⁵⁵ (See Cautions.)

Preparations

Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.

Ketorolac Tromethamine
Routes	Dosage Forms	Strengths	Brand Names	Manufacturer
Ophthalmic	Solution	0.4%	Acular LS (with benzalkonium chloride)	Allergan
		0.5%	Acular (with benzalkonium chloride)	Allergan
			Acular PF (preservative-free)	Allergan

Comparative Pricing

This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 03/2011. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.

Acular 0.5% Solution (ALLERGAN): 3/$59.34 or 9/$158.96

Acular 0.5% Solution (ALLERGAN): 5/$132.07 or 15/$370.21

Acular 0.5% Solution (ALLERGAN): 10/$236.03 or 30/$687.45

Acular LS 0.4% Solution (ALLERGAN): 5/$133.52 or 15/$400.6

Acuvail 0.45% Solution (ALLERGAN): 30/$133.11 or 90/$374.39

Ketorolac Tromethamine 0.4% Solution (FALCON PHARMACEUTICALS): 5/$75.99 or 15/$199.96

Disclaimer

This report on medications is for your information only, and is not considered individual patient advice. Because of the changing nature of drug information, please consult your physician or pharmacist about specific clinical use.

The American Society of Health-System Pharmacists, Inc. and Drugs.com represent that the information provided hereunder was formulated with a reasonable standard of care, and in conformity with professional standards in the field. The American Society of Health-System Pharmacists, Inc. and Drugs.com make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information and specifically disclaims all such warranties. Users are advised that decisions regarding drug therapy are complex medical decisions requiring the independent, informed decision of an appropriate health care professional, and the information is provided for informational purposes only. The entire monograph for a drug should be reviewed for a thorough understanding of the drug's actions, uses and side effects. The American Society of Health-System Pharmacists, Inc. and Drugs.com do not endorse or recommend the use of any drug. The information is not a substitute for medical care.

AHFS Drug Information. © Copyright, 1959-2011, Selected Revisions January 2007. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.

† Use is not currently included in the labeling approved by the US Food and Drug Administration.

References

1. Allergan. Acular (ketorolac tromethamine) ophthalmic solution 0.5% sterile prescribing information. Irvine, CA; 2002 Feb.

2. Syntex Laboratories Inc. Toradol (ketorolac tromethamine) tablets and injection prescribing information. Physicians’ desk reference. 47th ed. Montvale, NJ: Medical Economics Company Inc; 1993:2411-5.

3. Muchowski JM, Unger SH, Ackrell J et al. Synthesis and antiinflammatory and analgesic activity of 5-aroyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole -1-carboxylic acids and related compounds. J Med Chem. 1985; 28: 1037-49. [PubMed 4020827]

4. Rooks WH II, Maloney PJ, Shott LD et al. The analgesic and anti-inflammatory profile of ketorolac and its tromethamine salt. Drugs Exp Clin Res. 1985; 11:479-92. [PubMed 3879752]

5. Guzman A, Yuste F, Toscano RA et al. Absolute configuration of (-)-5-benzoyl-1,2-dihydro-3H-pyrrolo[1,2-a]pyrrole -1-carboxy lic acid, the active enantiomer of ketorolac. J Med Chem. 1986; 29:589-91. [PubMed 3959034]

6. Syntex Laboratories Inc, Palo Alto, CA: Personal communication on ketorolac 28:08.04.

7. Gu L, Strickley RG. Preformulation salt selection: physical property comparisons of the tris(hydroxymethyl)aminomethane (THAM) salts of four analgesic/antiinflammatory agents with the sodium salts and the free acids. Pharm Res. 1987; 4:255-7. [PubMed 3509292]

8. Insel PA. Analgesic-antipyretics and antiinflammatory agents: drugs employed in the treatment of rheumatoid arthritis and gout. In: Gilman AG, Rall TW, Nies AS, et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:638-81.

9. Fraser-Smith EB, Matthews TR. Effect of ketorolac on phagocytosis of Candida albicans by peritoneal macrophages. Immunopharmacology. 1988; 16:151-5. [PubMed 3075603]

10. Rooks WH II, Tomolonis AJ, Maloney PJ et al. The analgesic and anti-inflammatory profile of (±)-5-benzoyl-1,2-dihydro-3 H-pyrrolo[1,2a]pyrrole-1-carboxylic acid (rS -37619). Agents Actions. 1982; 12:684-90. [PubMed 6984594]

11. Flach AJ, Lavelle CJ, Olander KW et al. The effect of ketorolac tromethamine solution 0.5% in reducing postoperative inflammation after cataract extraction and intraocular lens implantation. Ophthalmology. 1988; 95:1279-84. [PubMed 3062540]

12. Fraser-Smith EB, Matthews TR. Effect of ketorolac on Pseudomonas aeruginosa ocular infection in rabbits. J Ocul Pharmacol. 1988; 4:101-9. [PubMed 3262701]

13. Fraser-Smith EB, Matthews TR. Effect of ketorolac on Candida albicans ocular infection in rabbits. Arch Ophthalmol. 1987; 105:264-7. [PubMed 3492994]

14. Buckley MMT, Brogden RN. Ketorolac: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs. 1990; 39:86-109. [PubMed 2178916]

15. Fraser-Smith EB, Matthews TR. Effect of ketorolac on herpes simplex virus type one ocular infection in rabbits. J Ocul Pharmacol. 1988; 4:321-6. [PubMed 3246566]

16. Ling TL, Combs DL. Ocular bioavailability and tissue distribution of [¹⁴C]ketorolac tromethamine in rabbits. J Pharm Sci. 1987; 76:289-94. [PubMed 3598886]

17. Flach AJ, Graham J, Kruger LP et al. Quantitative assessment of postsurgical breakdown of the blood-aqueous barrier following administration of 0.5% ketorolac tromethamine solution. Arch Ophthalmol. 1988; 106:344-7. [IDIS 239148] [PubMed 3345153]

18. Flach AJ, Kraff MC, Sanders DR et al. The quantitative effect of 0.5% ketorolac tromethamine solution and 0.1% dexamethasone sodium phosphate solution on postsurgical blood-aqueous barrier. Arch Ophthalmol. 1988; 106:480-3. [IDIS 240262] [PubMed 3355415]

19. Flach AJ, Jaffe NS, Akers WA. The effect of ketorolac tromethamine in reducing postoperative inflammation: double-mask parallel comparison with dexamethasone. Ann Ophthalmol. 1989; 21:407-11. [PubMed 2619149]

20. Flach AJ, Dolan BJ, Irvine AR. Effectiveness of ketorolac tromethamine 0.5% ophthalmic solution for chronic aphakic and pseudophakic cystoid macular edema. Am J Ophthalmol. 1987; 103:479-86. [IDIS 228104] [PubMed 3551617]

21. Syntex Laboratories Inc. Toradol product monograph. Palo Alto, CA; 1990 Mar.

22. Syntex Laboratories Inc. Toradol pharmacy information. Palo Alto, CA; 1990 Mar.

23. Flach AJ, Jampol LM, Weinberg D et al. Improvement in visual acuity in chronic aphakic and pseudophakic cystoid macular edema after treatment with topical 0.5% ketorolac tromethamine. Am J Ophthalmol. 1991; 112:514-9. [IDIS 290630] [PubMed 1951587]

24. CIBA Vision Ophthalmics. Voltaren Ophthalmic (diclofenac sodium) 0.1% sterile ophthalmic solution prescribing information. Physicians’ desk reference for ophthalmology. 21st ed. Montvale, NJ: Medical Economics Company Inc; 1993:273-4.

25. Budavari S, ed. The Merck index. 11th ed. Rahway, NJ: Merck & Co, Inc; 1989:836.

26. Syntex Laboratories Inc. Toradol formulary facts. Palo Alto, CA; 1990.

27. Anon. Ketorolac tromethamine. Med Lett Drugs Ther. 1990; 32:79- 82. [PubMed 2199809]

28. Gannon R. Focus on ketorolac: a nonsteroidal, anti-inflammatory agent for the treatment of moderate to severe pain. Hosp Formul. 1989; 24:695-702.

29. Yee JP, Koshiver JE, Allbon C et al. Comparison of intramuscular ketorolac tromethamine and morphine sulfate for analgesia of pain after major surgery. Pharmacotherapy. 1986; 6:253-61. [IDIS 394443] [PubMed 3540877]

30. Bloomfield SS, Mitchell J, Cissell GB et al. Ketorolac versus aspirin for postpartum uterine pain. Pharmacotherapy. 1986; 6:247-52. [IDIS 394442] [PubMed 3540876]

31. Reviewers’ comments (personal observations) on ketorolac.

32. Robinson DR. Prostaglandins and the mechanism of action of anti-inflammatory drugs. Am J Med. 1983; 10:26-31.

33. Koch-Weser J. Nonsteroidal antiinflammatory drugs (first of two parts). N Engl J Med. 1980; 302:1179-85. [IDIS 113555] [PubMed 6988717]

34. Abramson S, Edelson H, Kaplan H et al. Inhibition of neutrophil activation by nonsteroidal anti-inflammatory drugs. Am J Med. 1984; 10:3-6.

35. Deraedt R, Jouquey S, Benzoni J et al. Inhibition of prostaglandin biosynthesis by non-narcotic analgesic drugs. Arch Int Pharmacodyn Ther. 1976; 224:30-42. [PubMed 13749]

36. Atkinson DC, Collier HOJ. Salicylates: molecular mechanism of therapeutic action. Adv Pharmacol Chemother. 1980; 17:233-88. [PubMed 7004141]

37. Hart FD. Rheumatic disorders. In: Avery GS, ed. Drug treatment: principles and practice of clinical pharmacology and therapeutics. 2nd ed. New York: ADIS Press; 1987:846-61.

38. Haynes WL, Proia AD, Klintworth GK. Effect of inhibitors of arachidonic acid metabolism on corneal neovascularization in the rat. Invest Ophthalmol Vis Sci. 1989; 30:1588-93. [PubMed 2473047]

39. Mahoney JM, Waterbury LD. Drug effects on the neovascularization response to silver nitrate cauterization of the rat cornea. Curr Eye Res. 1985; 4:531-5. [PubMed 2410194]

40. Havener WH. Ocular pharmacology. 5th ed. St. Louis: The CV Mosby Company; 1983:18-43,223-35.

41. Conrad KA, Fagan TC, Mackie MJ et al. Effects of ketorolac tromethamine on hemostasis in volunteers. Clin Pharmacol Ther. 1988; 43:542-6. [IDIS 242096] [PubMed 3259170]

42. Spowart K, Greer IA, McLaren M et al. Haemostatic effects of ketorolac with and without concomitant heparin in normal volunteers. Thromb Haemost. 1988; 60:382-6. [PubMed 3266379]

43. Roe RL, Bruno JJ, Ellis DJ. Effects of a new nonsteroidal anti-inflammatory agent on platelet function in male and female subjects. Clin Pharmacol Ther. 1981; 29:277.

44. Bruno JJ, Yang D, Taylor LA. Differing effects of ticlopidine and two prostaglandin synthetase inhibitors on maximum rate of ADP-induced aggregation. Thromb Haemost. 1981; 46:412.

45. Mroszczak EJ, Lee FW, Combs D et al. Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animals and humans. Drug Metab Dispos. 1987; 15:618-26. [IDIS 235471] [PubMed 2891477]

46. Walker JJ, Johnstone J, Lloyd J et al. The transfer of ketorolac tromethamine from maternal to foetal blood. Eur J Clin Pharmacol. 1988; 34:509-11. [IDIS 244072] [PubMed 3264528]

47. Greer IA, Johnston J, Tulloch I et al. Effect of maternal ketorolac administration on platelet function in the newborn. Eur J Obstet Gynecol Reprod Biol. 1988; 29:257-60. [PubMed 3265921]

48. Wischnik A, Manth SM, Lloyd J. The excretion of ketorolac tromethamine into breast milk after multiple oral dosing. Eur J Clin Pharmacol. 1989; 36:521-4. [IDIS 255985] [PubMed 2787750]

49. Jung D, Mroszczak E, Bynum L. Pharmacokinetics of ketorolac tromethamine in humans after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol. 1988; 35:423-5. [IDIS 247775] [PubMed 3264245]

50. Jung D, Mroszczak EJ, Wu A et al. Pharmacokinetics of ketorolac and p-hydroxyketorolac following oral and intramuscular administration of ketorolac tromethamine. Pharm Res. 1989; 6:62-5. [PubMed 2717521]

51. Jallad NS, Garg DC, Martinez JJ et al. Pharmacokinetics of single-dose oral and intramuscular ketorolac tromethamine in the young and elderly. J Clin Pharmacol. 1990; 30:76-81. [IDIS 262959] [PubMed 2303585]

52. Sarnquist FH, Mroszczak EJ, Sevelius H. Absorption and metabolism of a new anti-inflammatory, analgesic agent. Clin Pharmacol Ther. 1981; 29:280.

53. Allergan Medical Optics. Ocufen Liquifilm (flurbiprofen sodium) 0.03% sterile ophthalmic solution prescribing information. Physicians’ desk reference for ophthalmology. Montvale, NJ: Medical Economics Company Inc; 1993:236-7.

54. Weinberger M. Analgesic sensitivity in children with asthma. Pediatrics. 1978; 62(Suppl):910-5. [IDIS 118712] [PubMed 103067]

55. Pleskow WW, Stevenson DD, Mathison DA et al. Aspirin desensitization in aspirin-sensitive asthmatic patients: clinical manifestations and characterization of the refractory period. J Allergy Clin Immunol. 1982; 69(1 Part 1):11-9. [IDIS 144037] [PubMed 7054250]

56. VanArsdel PP Jr. Aspirin idiosyncrasy and tolerance. J Allergy Clin Immunol. 1984; 73:431-3. [IDIS 183975] [PubMed 6423718]

57. Stevenson DD. Diagnosis, prevention, and treatment of adverse reactions to nonsteroidal anti-inflammatory drugs. J Allergy Clin Immunol. 1984; 74(4 Part 2):617-22. [IDIS 193318] [PubMed 6436354]

58. Stevenson DD, Mathison DA. Aspirin sensitivity in asthmatics: when may this drug be safe? Postgrad Med. 1985; 78:111-3,116-9.

59. Settipane GA. Aspirin and allergic diseases: a review. Am J Med. 1983; 74(Suppl):102-9. [IDIS 171763] [PubMed 6344621]

60. Indocin (indomethacin) capsules, oral suspension, and suppositories prescribing information. In: Barnhart ER, ed. Physicians’ desk reference. 44th ed. Oradell, NJ: Medical Economics Company Inc; 1990:1395-8.

61. Flach AJ, Stegman RC, Graham J et al. Prophylaxis of aphakic cystoid macular edema without corticosteroids. A paired-comparison, placebo-controlled double -masked study. Ophthalmology. 1990; 97:1253-8. [PubMed 2243674]

62. Bhattacherjee P. Prostaglandins and inflammatory reactions in the eye. Methods Find Exp Clin Pharmacol. 1980; 2:17-31. [PubMed 6803089]

63. Eakins KE. Prostaglandin and non-prostaglandin mediated breakdown of the blood-aqueous barrier. Exp Eye Res. 1977; 25(Suppl):483-98. [PubMed 338326]

64. Podos SM, Becker B. Comparison of ocular prostaglandin synthesis inhibitors. Invest Ophthalmol. 1976; 15:841-4. [PubMed 977253]

65. Duffin RM, Camras CB, Gardner SK et al. Inhibitors of surgically induced miosis. Ophthalmology. 1982; 89:966-78. [PubMed 7133642]

66. Kulkarni PS, Srinivasan BD. Comparative in vivo inhibitory effects of nonsteroidal anti-inflammatory agents on prostaglandin synthesis in rabbit ocular tissues. Arch Ophthalmol. 1985; 103:103-6. [PubMed 3919694]

67. Leopold IH, Murray D. Noncorticosteroidal anti-inflammatory agents in ophthalmology. Ophthalmology. 1979; 86:142-55. [PubMed 394060]

68. van Alphen GWHM, Dutilh CE, de Deckere EAM. The high yield of prostacyclin biosynthesis by the iris and its effects on the intraocular muscles. Prostaglandins Med. 1978; 1:151-8. [PubMed 362455]

69. Hall DWR, Bonta IL. Prostaglandins and ocular inflammation. Doc Ophthalmol. 1977; 2:421-34.

70. Kass MA, Holmberg NJ. Prostaglandin and thromboxane synthesis by microsomes of rabbit ocular tissues. Invest Ophthalmol Vis Sci. 1979; 18:166-71. [PubMed 761971]

71. Sawa M, Masuda K. Topical indomethacin in soft cataract aspiration. Jpn J Ophthalmol. 1976; 20:514-9.

72. Ciprandi G, Buscaglia S, Cerqueti PM et al. Drug treatment of allergic conjunctivitis: a review of the evidence. Drugs. 1992; 43:154-76. [IDIS 360840] [PubMed 1372215]

73. Abelson MB, Butrus SI, Kliman GH et al. Topical arachidonic acid: a model for screening anti-inflammatory agents. J Ocul Pharmacol. 1987; 3:63-75. [PubMed 3141537]

74. Friedlaender MH. Current concepts in ocular allergy. Ann Allergy. 1991; 67:5-10,13. [IDIS 312766] [PubMed 1859041]

75. Helleboid L, Khatami M, Wei ZG et al. Histamine and prostacyclin: primary and secondary release in allergic conjunctivitis. Invest Ophthalmol Vis Sci. 1991; 32:2281-9. [PubMed 1712764]

76. Abramson SB, Weissmann G. The mechanisms of action of nonsteroidal antiinflammatory drugs. Arthritis Rheum. 1989; 32:1-9. [IDIS 250500] [PubMed 2643434]

77. Trocme SD. Medical therapy for ocular allergy. Mayo Clin Proc. 1992; 67:557-65. [IDIS 296611] [PubMed 1359206]

78. Brocks DR, Jamali F. Clinical pharmacokinetics of ketorolac tromethamine. Clin Pharmacokinet. 1992; 23:415-27. [PubMed 1458761]

79. Sabiston D, Tessler H, Sumers K et al. Reduction of inflammation following cataract surgery by the nonsteroidal anti-inflammatory drug, flurbiprofen. Ophthalmic Surg. 1987; 18:873-7. [PubMed 3502173]

80. Bhattacherjee P. The role of arachidonate metabolites in ocular inflammation. Prog Clin Biol Res. 1989; 312:211-27. [PubMed 2508125]

81. Flach AJ. Cyclo-oxygenase inhibitors in ophthalmology. Surv Ophthalmol. 1992; 36:259-84. [PubMed 1549810]

82. Buckley DC, Caldwell DR, Reaves TA Jr. Treatment of vernal conjunctivitis with suprofen, a topical nonsteroidal anti-inflammatory agent. Invest Ophthalmol Vis Sci. 1986; 27:29. [IDIS 213714] [PubMed 3941035]

83. Wood TS, Stewart RH, Bowman RW et al. Suprofen treatment of contact lens-associated giant papillary conjunctivitis. Ophthalmology. 1988; 95:822-6. [PubMed 3211485]

84. Gupta S, Khurana AK, Ahluwalia BK et al. Topical indomethacin for vernal keratoconjunctivitis. Acta Opthalmol (Copenh). 1991; 69:95-8.

85. Allergan. Acular (ketorolac tromethamine) prescribing information. In: Krogh CME, ed. Compendium of pharmaceuticals and specialties 1993. 28th ed. Ottawa, Ontario: Canadian Pharmaceutical Association; 1993:23.

86. CIBA Vision. Voltaren Ophthalmic (diclofenac sodium) prescribing information. In: Krogh CME, ed. Compendium of pharmaceuticals and specialties 1993. 28th ed. Ottawa, Ontario: Canadian Pharmaceutical Association; 1993:1333-4.

87. Merck Sharp and Dohme. Indocid (indomethacin) ophthalmic suspension prescribing information. In: Krogh CME, ed. Compendium of pharmaceuticals and specialties 1993. 28th ed. Ottawa, Ontario: Canadian Pharmaceutical Association; 1993:583.

88. Asbell PA, Torres MA. Therapeutic dilemmas in external ocular diseases. Drugs. 1991; 42:606-15. [PubMed 1723363]

89. Leibowitz HM, Ryan WJ, Kupferman A et al. Bioavailability of corneal anti-inflammatory effect of topical suprofen. Invest Ophthalmol Vis Sci. 1986; 27:628-31. [PubMed 3957583]

90. Leibowitz HM, Ryan WJ, Kupferman A et al. Effect of concurrent topical corticosteroid and NSAID therapy of experimental keratitis. Invest Ophthalmol Vis Sci. 1986; 27:1226-9. [PubMed 3733368]

91. Kraff MC, Sanders DR, McGuigan L et al. Inhibition of blood-aqueous humor barrier breakdown with diclofenac: a fluorophotometric study. Arch Ophthalmol. 1990; 108:380-3. [IDIS 296047] [PubMed 2178597]

92. Bito LZ. Surgical miosis: have we been misled by a bunch of rabbits? Ophthalmology. 1990; 97:1-2. Letter.

93. Kraff MC, Sanders DR, Jampol LM et al. Factors affecting pseudophakic cystoid macular edema: five randomized trials. J Am Intraocul Implant Soc. 1985; 11:380-5. [PubMed 4030486]

94. Gnad HD, Paroussis P, Skorpik C. Treatment of cystoid macular edema after intracapsular cataract extraction and implantation of the Binkhorst 4-loop lens. (German; with English abstract.) Wien Klin Wochenschr. 1985; 97:625-7.

95. Alpar JJ. Posterior capsulotomy in sulcus-fixated versus bag-fixated intraocular lenses in diabetic patients. J Am Intraocul Implant Soc. 1985; 11:577-80. [PubMed 4077672]

96. Jampol LL. Pharmacologic therapy of aphakic and pseudophakic cystoid macular edema. 1985 update. Ophthalmology. 1985; 92:807-10. [PubMed 3897936]

97. Lambrix K. Cystoid macular edema: a postoperative complication. J Ophthalmic Nurs Technol. 1990; 9:152-4. [PubMed 2374166]

98. Peterson M, Yoshizumi MO, Hepler R et al. Topical indomethacin in the treatment of chronic cystoid macular edema. Graefes Arch Clin Exp Ophthalmol. 1992; 230:401-5. [PubMed 1521802]

99. Sears ML. Aphakic cystoid macular edema. The pharmacology of ocular trauma. Surv Ophthalmol. 1984; 28(Suppl):525-34. [PubMed 6379950]

100. Yannuzzi LA. A perspective on the treatment of aphakic cystoid macular edema. Surv Ophthalmol. 1984; 28(Suppl):540-53. [PubMed 6379952]

101. Yannuzzi LA, Landau AN, Turtz AL. Incidence of aphakic cystoid macular edema with the use of topical indomethacin. Ophthalmolgy. 1981; 88:947-54.

102. Kraff MC, Sanders DR, Jampol LM et al. Prophylaxis of pseudophakic cystoid macular edema with topical indomethacin. Ophthalmology. 1982; 89:885-90. [PubMed 6752799]

103. Miyake K, Sakamura S, Miura H. Long-term follow-up study on the prevention of aphakic cystoid macular edema by topical indomethacin. Br J Ophthalmol. 1980; 64:324-8. [PubMed 7437393]

104. Foster CS, Calonge M. Atopic keratoconjunctivitis. Ophthalmology. 1990; 97:992-100. [PubMed 1976238]

105. Foster CS, Rice BA, Dutt JE. Immunopathology of atopic keratocomjunctivitis. Ophthalmology. 1991; 98:1190-6. [PubMed 1923355]

106. Alcon Laboratories. Profenal (suprofen) 1% sterile ophthalmic solution prescribing information. In: Physicians’ desk reference for ophthalmology. 21st ed. Montvale, NJ: Medical Economics Company; 1993;233-5.

107. Stark WJ, Fagadau WR, Stewart RH et al. Reduction of pupillary constriction during cataract surgery using suprofen. Arch Ophthalmol. 1986; 104:364-6. [IDIS 212468] [PubMed 3513744]

108. Keates RH, McGowan KA. Clinical trial of flurbiprofen to maintain pupillary dilation during cataract surgery. Ann Ophthalmol. 1984; 16:919-21. [PubMed 6391333]

109. Camras CR, Miranda OC. The putative role of prostaglandins in surgical miosis. Prog Clin Biol Res. 1989; 312:197-210. [PubMed 2508124]

110. Goa KL, Chrisp P. Ocular diclofenac: a review of its pharmacology and clinical use in cataract surgery, and potential in other inflammatory ocular conditions. Drugs Aging. 1992; 2:473-86. [PubMed 1493352]

111. Green K, Cheeks L, Luxenberg MN. Topical indomethacin and prostaglandins in normal and aphakic rabbit eyes. Curr Eye Res. 1988; 7:1105-11. [PubMed 3243084]

112. Hersh PS, Rice BA, Baer JC et al. Topical nonsteroidal agents and corneal wound healing. Arch Ophthalmol. 1990; 108:577-83. [PubMed 2322160]

113. Trousdale MD, Dunkel EC, Nesburn AB. Effect of flurbiprofen on herpes simplex keratitis in rabbits. Invest Ophthalmol Vis Sci. 1980; 19:267-70. [PubMed 7358477]

114. Trousdale MD, Barlow WE, McGuigan LJB. Assessment of diclofenac on herpes keratitis in rabbit eyes. Arch Ophthalmol. 1989; 107: 1664-6.

115. Allergan Medical Optics. Ocufen Liquifilm (flurbiprofen sodium) 0.03% sterile ophthalmic solution prescribing information. Physicians’ desk reference for ophthalmology. 20th ed. Montvale, NJ: Medical Economics Company Inc; 1992:236-7.

116. Haynes RC Jr. Adrenocorticotropic hormone: adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Gilman AG, Rall TW, Nies AS, et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:1431-62.

117. Haddow GR, Riley E, Isaacs R et al. Ketorolac, nasal polyposis, and bronchial asthma: a cause for concern. Anesth Analg. 1993; 76:420-2. [IDIS 310160] [PubMed 8424525]

118. Zikowski D, Hord AH, Haddox JD et al. Ketorolac-induced bronchospasm. Anesth Analg. 1993; 76:417-9. [IDIS 310159] [PubMed 8424524]

119. Campbell WB. Lipid-derived autacoids: eicosanoids and platelet -activating factor. In: Gilman AG, Rall TW, Nies AS, et al, eds. Goodman and Gilman’s the pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press; 1990:600 -605.

120. Flower RJ, Blackwell GJ. Anti-inflammatory steroids induce biosynthesis of a phospholipase A₂ inhibitor which prevents PG production. Nature. 1979; 278:456 -9. [PubMed 450050]

121. Kremer M, Baikoff G, Charbonnel B. The release of prostaglandins in human aqueous humour following intraocular surgery: effect of indomethacin. Prostaglandins. 1982; 23:695-702. [PubMed 6956947]

122. Kremer M, Baikoff G, Charbonnel B. Prostaglandin E2 in side effects of ocular surgery in man: preventive action of indomethacin. Adv Prostaglandin Thromboxane Leukot Res. 1983; 12:121-6. [PubMed 6221587]

123. Miyake K, Sugiyama S, Norimatsu I et al. Prevention of cystoid macular edema after lens extraction by topical indomethacin (III) radioimmunoassay measurement of prostaglandins in the aqueous during and after lens extraction procedures. Graefes Arch Klin Exp Ophthalmol. 1978; 209:83-8.

124. Miyake K. Prevention of cystoid macular edema after lens extraction by topical indomethacin (I): a preliminary report. Graefes Arch Klin Exp Ophthalmol. 1977; 203:81-8.

125. Miyake K. Prophylaxis of aphakic cystoid macular edema using topical indomethacin. J Am Intraocul Implant Soc. 1978; 4:174-9. [PubMed 748308]

126. Paterson CA, Eakins KE, Paterson E et al. The ocular hypertensive response following experimental acid burns in the rabbit eye. Invest Ophthalmol Vis Sci. 1979; 18:67-74. [PubMed 32151]

127. Rowland JM, Ford CJ, Della Puca RA et al. Effects of topical diclofenac sodium in a rabbit model of ocular inflammation and leukotaxis. J Ocul Pharmacol. 1986; 2:23-9. [PubMed 3509726]

128. Bhattercherjee P, Eakins KE. Inhibition of the ocular effects of sodium arachidonate by anti-inflammatory compounds. Prostaglandins. 1975; 9:175-82. [PubMed 1135434]

Saturday, 3 March 2012

Maxiphen CDX

Generic Name: codeine, guaifenesin, and phenylephrine (KOE deen, gwye FEN e sin, FEN il EFF rin)

Brand Names: Maxiphen CD, Maxiphen CDX

What is Maxiphen CDX (codeine, guaifenesin, and phenylephrine)?

Codeine is in a group of drugs called narcotics. It is a cough suppressant that affects the signals in the brain that trigger cough reflex.

Guaifenesin is an expectorant. It helps loosen mucus congestion in your chest and throat, making it easier to cough out through your mouth.

Phenylephrine is a decongestant that shrinks blood vessels in the nasal passages. Dilated blood vessels can cause nasal congestion (stuffy nose).

The combination of codeine, guaifenesin, and phenylephrine is used to treat cough, nasal, and sinus congestion, and to reduce chest congestion caused by upper respiratory infections or the common cold.

Codeine, guaifenesin, and phenylephrine may also be used for purposes other than those listed in this medication guide.

What is the most important information I should know about Maxiphen CDX (codeine, guaifenesin, and phenylephrine)?

Do not take this medication if you have used an MAO inhibitor such as isocarboxazid (Marplan), phenelzine (Nardil), rasagiline (Azilect), selegiline (Eldepryl, Emsam), or tranylcypromine (Parnate) within the past 14 days. Serious, life-threatening side effects can occur if you take cough or cold medicine before the MAO inhibitor has cleared from your body. Do not use any other over-the-counter cough or cold medication without first asking your doctor or pharmacist. If you take certain products together you may accidentally take too much of one or more types of medicine. Read the label of any other medicine you are using to see if it contains guaifenesin or phenylephrine. Codeine may be habit-forming and should be used only by the person it was prescribed for. This medication should never be shared with another person, especially someone who has a history of drug abuse or addiction. Keep the medication in a secure place where others cannot get to it. Always ask a doctor before giving a cough or cold medicine to a child. Death can occur from the misuse of cough and cold medicines in very young children.

What should I discuss with my healthcare provider before taking Maxiphen CDX (codeine, guaifenesin, and phenylephrine)?

severe or uncontrolled high blood pressure;

severe coronary artery disease;

enlarged prostate; or

if you are breast-feeding a baby.

If you have certain conditions, you may need a dose adjustment or special tests to safely take codeine, guaifenesin, and phenylephrine. Before taking this medication, tell your doctor if you are allergic to any drugs, or if you have:

heart disease or high blood pressure;

ischemic heart disease (reduced circulation of blood to the heart);

asthma, COPD, sleep apnea, or other breathing disorders;

diabetes;

a thyroid disorder;

glaucoma;

a history of head injury or brain tumor;

epilepsy or other seizure disorder;

liver or kidney disease;

a stomach or intestinal disorder;

Addison's disease or other adrenal gland disorders; or

if you have recently had stomach, bladder, or kidney surgery.

FDA pregnancy category C. This medication may be harmful to an unborn baby, and could cause addiction or withdrawal symptoms in a newborn. Tell your doctor if you are pregnant or plan to become pregnant during treatment. Codeine can pass into breast milk and may harm a nursing baby. The use of codeine by some nursing mothers may lead to life-threatening side effects in the baby. Do not use this medication if you are breast-feeding a baby. Codeine may be habit-forming and should be used only by the person it was prescribed for. Codeine should never be shared with another person, especially someone who has a history of drug abuse or addiction. Keep the medication in a secure place where others cannot get to it. Codeine is a drug of abuse and you should be aware if any person in the household is using this medicine improperly or without a prescription. Older adults may be more likely to have side effects from this medication.

How should I take Maxiphen CDX (codeine, guaifenesin, and phenylephrine)?

Take this medication exactly as it has been prescribed by your doctor. Do not use the medication in larger amounts, or use it for longer than recommended. Cough or cold medicine is usually taken only for a short time until your symptoms clear up.

Always ask a doctor before giving cough or cold medicine to a child. Death can occur from the misuse of cough or cold medicine in very young children. Take codeine, guaifenesin, and phenylephrine with food if it upsets your stomach. Call your doctor if your symptoms do not improve after 7 days of treatment, or if you also have a fever, headache, or skin rash.

This medication can cause you to have unusual results with certain medical tests. Tell any doctor who treats you that you are using codeine guaifenesin, and phenylephrine.

Store this medicine at room temperature, away from heat, light, and moisture.

Keep track of how many pills have been used from each new bottle of this medicine. Codeine is a drug of abuse and you should be aware if any person in the household is using this medicine improperly or without a prescription.

What happens if I miss a dose?

Since cough or cold medicine is usually taken only as needed, you may not be on a dosing schedule. If you are taking the medication regularly, take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose and take the medicine at your next regularly scheduled time. Do not take extra medicine to make up the missed dose.

What happens if I overdose?

Seek emergency medical attention if you think you have used too much of this medicine. An overdose of codeine can be fatal.

Overdose symptoms may include extreme dizziness or drowsiness, nausea, vomiting, stomach, sweating, confusion, hallucinations, cold and clammy skin, blue-colored lips or fingernails, weak or limp muscles, pinpoint pupils, weak pulse, slow breathing, fainting, or seizures (convulsions).

What should I avoid while taking Maxiphen CDX (codeine, guaifenesin, and phenylephrine)?

This medication can cause side effects that may impair your thinking or reactions. Be careful if you drive or do anything that requires you to be awake and alert.

Do not use any other over-the-counter cough, cold, pain, or allergy medication without first asking your doctor or pharmacist. Guaifenesin and phenylephrine are contained in many medicines available over the counter. If you take certain products together you may accidentally take too much of a certain drug. Read the label of any other medicine you are using to see if it contains guaifenesin or phenylephrine.

Avoid drinking alcohol. It can increase some of the side effects of this medication.

Maxiphen CDX (codeine, guaifenesin, and phenylephrine) side effects

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat. Stop taking this medication and call your doctor at once if you have any of these serious side effects:

severe dizziness, anxiety, restless feeling, or nervousness, tremors;

confusion, hallucinations, unusual thoughts or behavior;

seizure (convulsions);

fast, pounding, or uneven heartbeat;

slow heart rate, weak pulse, fainting, weak or shallow breathing; or

increased blood pressure (severe headache, blurred vision, trouble concentrating, chest pain, numbness, seizure).

Less serious side effects include:

dizziness, drowsiness, headache;

nausea, vomiting;

constipation;

feeling excited or restless;

sleep problems (insomnia);

warmth, tingling, or redness under your skin; or

skin rash or itching.

This is not a complete list of side effects and others may occur. Tell your doctor about any unusual or bothersome side effect. You may report side effects to FDA at 1-800-FDA-1088.

What other drugs will affect Maxiphen CDX (codeine, guaifenesin, and phenylephrine)?

Before taking this medication, tell your doctor if you regularly use other medicines that make you sleepy (such as allergy medicine, narcotic pain medicine, sleeping pills, muscle relaxers, and medicine for seizures, depression, or anxiety). They can add to sleepiness caused by codeine or guaifenesin.

Also tell your doctor if you are using any of the following drugs:

medicines to treat high blood pressure;

indomethacin (Indocin);

mecamylamine (Inversine);

methyldopa (Aldomet);

reserpine;

a beta-blocker such as atenolol (Tenormin), carteolol (Cartrol), metoprolol (Lopressor, Toprol), nadolol (Corgard), propranolol (Inderal), sotalol (Betapace), timolol, and others; or

an antidepressant such as amitriptyline (Elavil), clomipramine (Anafranil), imipramine (Janimine, Tofranil), and others.

This list is not complete and there may be other drugs that can interact with codeine, guaifenesin, and phenylephrine. Tell your doctor about all the prescription and over-the-counter medications you use. This includes vitamins, minerals, herbal products, and drugs prescribed by other doctors. Do not start using a new medication without telling your doctor.

More Maxiphen CDX resources

Maxiphen CDX Use in Pregnancy & Breastfeeding
Maxiphen CDX Drug Interactions
Maxiphen CDX Support Group
0 Reviews for Maxiphen CDX - Add your own review/rating

Codeine/Guaifenesin/Phenylephrine Liquid MedFacts Consumer Leaflet (Wolters Kluwer)

Compare Maxiphen CDX with other medications

Cough and Nasal Congestion

Where can I get more information?

Your pharmacist can provide more information about codeine, guaifenesin, and phenylephrine.

Thursday, 1 March 2012

Provigil

PROVIGIL Tablets 100 mg/200 mg

(Modafinil)

Read all of this leaflet carefully before you start taking this medicine.

Keep this leaflet. You may need to read it again.

If you have any further questions, ask your doctor or pharmacist.

This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours.

If any of the side effects get serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.

In this leaflet:

1. What PROVIGIL is and what it is used for.

2. Before you take PROVIGIL.

3. How to take PROVIGIL.

4. Possible side effects.

5. How to store PROVIGIL.

6. Further information.

What Provigil Is And What It Is Used For

The name of your medicine is PROVIGIL 100 mg or 200 mg tablets. The active ingredient in them is modafinil.

PROVIGIL is a medicine that helps people with sleep problems stay awake, including the following medical conditions; narcolepsy, obstructive sleep apnoea or a moderate to severe sleep disorder (i.e. due to shift work patterns).

Before You Take Provigil

Do not take PROVIGIL if you:

Are allergic (hypersensitive) to modafinil, or any of the other ingredients of PROVIGIL.

Are pregnant, planning to become pregnant or breast-feeding.

Have an irregular heartbeat.

Have uncontrolled, moderate/severe high blood pressure (hypertension).

PROVIGIL is not recommended for children.

Take Special Care with PROVIGIL if you:

Have any heart problems.

Have an abnormal heart beat.

Have problems with excessive anxiety.

Have high blood pressure (hypertension).

Have kidney disease.

Have liver disease.

Are over 65 years of age.

Have ever had depression, low mood, psychosis (loss of contact with reality) or mania (over excitation).

If any of the above apply to you, you should speak to your doctor before taking this medicine.

Some people have reported suicidal or aggressive thoughts or behaviour while taking PROVIGIL. Be sure to tell your doctor if you notice that you are becoming depressed or have suicidal thoughts or changes in your behaviour. You may want to consider asking a family member or close friend to help you stay alert to signs of depression or changes in your behaviour.

Although this medicine has a low potential for dependence, the chance of this happening with long-term use cannot be completely ruled out.

Taking with other medicines

Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without prescription. It is especially important if you are taking:

Hormonal contraceptives (including the contraceptive pill, implants, intrauterine devices (IUDs) and patches). Talk to your doctor about birth control methods that are right for you while using PROVIGIL, and for two months after stopping PROVIGIL.

Medicines for acid reflux (eg omeprazole).

Antiviral medicines (protease inhibitors).

Ciclosporin (eg used in organ transplants, arthritis and psoriasis).

Medicines for epilepsy (eg phenytoin).

Medicines for depression or anxiety.

Medicines for thinning the blood (eg warfarin).

Medicines for high blood pressure or heart problems (eg calcium channel blockers).

Medicines for lowering cholesterol (statins).

Betablockers (eg propanalol).

Pregnancy and breast-feeding

If you are pregnant, think you might be or are breast-feeding you should not take PROVIGIL. It is not known if PROVIGIL may harm your unborn baby.

Driving and operating machinery

PROVIGIL can sometimes cause blurred vision or dizziness in some people. If you are affected or you find that using this medication makes you feel excessively sleepy, do not attempt to drive or operate machinery.

Important information about one of the ingredients of PROVIGIL

These tablets contain lactose. If your doctor has told you that you have an intolerance to some sugars, you should contact them before taking this medicine.

How To Take Provigil

Always take PROVIGIL exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure.

Narcolepsy and sleep apnoea

The usual dose is 200 to 400 mg a day. This can be taken once daily (in the morning) or twice daily (in the morning and at midday).

Moderate to severe chronic shift work sleep disorder

The recommended dose is 200 mg, once a day (approximately 1 hour before the start of a night shift).

Your doctor may sometimes prescribe a lower dose than this, depending on your individual circumstances.

Tablets should be swallowed whole with water.

If you take more PROVIGIL than you should

If you take too much PROVIGIL contact your nearest hospital casualty department or tell your doctor or pharmacist immediately. Take this leaflet and any remaining tablets with you.

If you forget to take PROVIGIL

If you forget to take PROVIGIL take the next dose at the usual time, do not take a double dose to make up for the forgotten one.

If you have any further questions on the use of this product, ask your doctor or pharmacist.

Provigil Side Effects

Like all medicines, PROVIGIL can cause side effects, although not everybody gets them.

Stop taking this medicine and tell your doctor immediately if you have difficulty breathing or your mouth or throat begins to swell or if you start suffering from a severe rash, itching or other skin reactions, as these may be signs of an allergic reaction.

Other side effects include the following:

Very common side effects (affecting more than 1 in 10 people):

Headache.

Common side effects (affecting between 1 in 10 and 1 in 100 people):

An irregular or fast heartbeat.

Chest pain, stomach pain, indigestion.

Weakness, flushing, feeling sick, dizziness, dry mouth.

Diarrhoea, constipation, loss of appetite.

Nervousness, anxiety, depression, abnormal thinking, confusion.

Difficulty sleeping (insomnia), sleepiness, excessive tiredness.

Pins and needles, blurred vision, abnormal liver function tests.

Uncommon side effects (affecting between 1 in 100 and 1 in 1,000 people):

Back pain, neck pain, muscle soreness, muscle weakness, leg cramps, joint pain, twitching.

Difficulty moving muscles smoothly, muscle tension, coordination problems, movement disorder.

Minor allergic reactions (such as hayfever), shortness of breath, itchy/runny nose, increased cough, asthma, sore throat.

Skin rash, acne, itchy skin, excessive sweating.

Increased blood pressure, abnormal heart tests, irregular or unusually slow heart beat, high/low blood pressure.

Excess wind, reflux (bringing back fluid from the stomach), increased appetite, thirst, taste alteration.

Being sick, migraine, speech disorder.

Difficulty swallowing, sore tongue, mouth ulcers.

Diabetes, blood disorders, increased blood cholesterol or blood sugar.

Swelling of hands and feet, weight changes.

Over-activity, agitation, tremor, vertigo, hostile behaviour, feeling detached, numbness, personality disorder.

Sleep disturbance, abnormal dreams, mood swings, aggression, forgetfulness, loss of sex drive.

Nose bleeds, inflamed nasal passages (sinuses).

Abnormal vision, dry eyes, abnormal urine, more frequent urination, abnormal periods.

In addition, if you experience any of the following you should tell your doctor immediately:

Psychological effects e.g. mood elation and over excitation, suicidal behaviour, agitation, and/or psychosis (a loss of contact with reality which may include delusions or hearing sounds that are not there).

Severe rash that may cause peeling of the skin.

Sudden wheeziness, difficulty breathing, swelling, rash or itching, especially if it affects your whole body.

If any of these side effects become serious or you experience any side effects not listed, please tell your doctor or pharmacist.

How To Store Provigil

Keep out of the reach and sight of children.

Do not take this medicine after the expiry date shown on the pack.

Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.

Further Information

What PROVIGIL contains

Each tablet contains modafinil (either 100 mg or 200 mg) as the active ingredient. In addition the tablets also contain lactose monohydrate, pregelatinised starch, microcrystalline cellulose, croscarmellose sodium, povidone and magnesium stearate as inactive ingredients.

What PROVIGIL looks like and the contents of the pack

The tablets come in a capsule shaped, white to off-white colour.

They are supplied in packs of blister strips and each box contains 30 tablets.

Marketing Authorisation Holder

Cephalon UK Limited

1 Albany Place

Hyde Way

Welwyn Garden City

Hertfordshire

AL7 3BT

Manufacturers

Laboratoires Macors

Rue des Caillottes

ZI Plaine des Isles

89000 Auxerre

France

And

Cephalon France

20 rue Charles Martigny

94700 Maisons-Alfort

France

This leaflet was last approved in September 2009

For more information please call free on 0800 783 4869 or e-mail: UKMedlnfo@cephalon.com

Additional information is available from various sources including the British Snoring & Sleep Apnoea Association (www.britishsnoring.co.uk, tel. 01737 245638).

08612-1596/1

Monday, 27 February 2012

Coldloc-LA

Generic Name: guaifenesin and phenylpropanolamine (gwye FEN e sin/fen ill proe pa NOLE a meen)

Brand Names: Ami-Tex LA, Banex-LA, Coldloc-LA, Dayquil Sinus Pressure and Congestion, Despec, Entex LA, Exgest LA, G-Vent, Guaifenex PPA 75, Guaivent, Guiatex LA, Naldecon-EX Pediatric, Nasahist LA, Phentex-LA, Phenylfenesin LA, Poly-Vent, Profen LA, Stamoist LA, Triaminic Expectorant, Vanex-LA

What is Coldloc-LA (guaifenesin and phenylpropanolamine)?

Guaifenesin is an expectorant. It is used to break up congestion and mucous to make breathing easier. Guaifenesin thins mucous, increases lubrication of the respiratory tract (lungs, nose and throat), and increases the removal of mucous.

Phenylpropanolamine is a decongestant. It constricts (shrinks) blood vessels (veins and arteries), which reduces swelling of mucous membranes in areas such as the nose and sinuses.

Guaifenesin and phenylpropanolamine is used to treat the symptoms of the common cold and of infections of the sinuses, lungs, and throat.

Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.

Guaifenesin and phenylpropanolamine may also be used for purposes other than those listed in this medication guide.

What is the most important information I should know about Coldloc-LA (guaifenesin and phenylpropanolamine)?

Drink plenty of extra fluids while taking this medication. Do not crush or chew the tablets. Swallow them whole or break them in half where they are scored to make them easier to swallow if needed.

Who should not take Coldloc-LA (guaifenesin and phenylpropanolamine)?

Do not take guaifenesin and phenylpropanolamine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Before taking this medication, tell your doctor if you have

high blood pressure or any other type of heart disease,

diabetes,

a peripheral vascular disorder (poor circulation),

glaucoma or increased pressure in the eyes,

an overactive thyroid, or

difficulty urinating or an enlarged prostate.

You may not be able to take guaifenesin and phenylpropanolamine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.

Guaifenesin and phenylpropanolamine is in the FDA pregnancy category C. This means that it is not known whether guaifenesin and phenylpropanolamine will harm an unborn baby. Do not take this medication without first talking to your doctor if you are pregnant. This medication passes into breast milk and may harm a nursing baby. Do not take this medication without first talking to your doctor if you are breast-feeding a baby. If you are over 65 years of age, you may be more likely to experience side effects from guaifenesin and phenylpropanolamine. You may require a lower dose of this medication. Guaifenesin and phenylpropanolamine has not been approved for use by children younger than 6 years of age.

How should I take Coldloc-LA (guaifenesin and phenylpropanolamine)?

Take guaifenesin and phenylpropanolamine exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.

Take each dose with a full glass of water. Increasing fluid intake during the day may help relieve congestion. Take guaifenesin and phenylpropanolamine with food if it causes stomach upset. Do not crush or chew the tablets. Swallow them whole or break them in half where they are scored to make them easier to swallow if needed. Store guaifenesin and phenylpropanolamine at room temperature away from moisture and heat.

What happens if I miss a dose?

Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication.

What happens if I overdose?

Seek emergency medical attention.

Symptoms of a guaifenesin and phenylpropanolamine overdose include vomiting, high blood pressure (headache, redness of face, blurred vision), an irregular heartbeat, and numbness of the fingers or toes.

What should I avoid while taking Coldloc-LA (guaifenesin and phenylpropanolamine)?

Use caution when driving, operating machinery, or performing other hazardous activities. Guaifenesin and phenylpropanolamine may cause dizziness. If you experience dizziness, avoid these activities.

Coldloc-LA (guaifenesin and phenylpropanolamine) side effects

No serious side effects from guaifenesin and phenylpropanolamine are expected. Seek emergency medical attention if you experience an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives).

Other, less serious side effects may be more likely to occur. Continue to take guaifenesin and phenylpropanolamine and talk to your doctor if you experience

dizziness or headache;

nervousness, restlessness, or insomnia;

nausea or stomach upset; or

difficulty urinating.

Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.

What other drugs will affect Coldloc-LA (guaifenesin and phenylpropanolamine)?

Heart medications such as methyldopa (Aldomet), reserpine (Serpalan, Serpasil), and guanethidine (Ismelin) may have decreased effects. Talk to your doctor before taking guaifenesin and phenylpropanolamine if you are taking any of these medications.

Do not take other over-the-counter cough, cold, allergy, diet, or sleep aids while taking guaifenesin and phenylpropanolamine without first talking to your doctor or pharmacist. Other medications may also contain guaifenesin, phenylpropanolamine, or other similar drugs. You may accidentally take too much of these medicines.

Drugs other than those listed here may also interact with guaifenesin and phenylpropanolamine. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.

More Coldloc-LA resources

Coldloc-LA Side Effects (in more detail)
Coldloc-LA Use in Pregnancy & Breastfeeding
Coldloc-LA Drug Interactions
Coldloc-LA Support Group
0 Reviews for Coldloc-LA - Add your own review/rating

Compare Coldloc-LA with other medications

Cough and Nasal Congestion

Where can I get more information?

Your pharmacist has additional information about guaifenesin and phenylpropanolamine written for health professionals that you may read.

What does my medication look like?

Guaifenesin and phenylpropanolamine is available with a prescription under several brand names. Ask your pharmacist any questions you have about this medication, especially if it is new to you.

Entex LA, 400 mg of guaifenesin and 75 mg of phenylpropanolamine--orange, scored tablets

Exgest LA, 400 mg of guaifenesin and 75 mg of phenylpropanolamine--white, oval-shaped, scored, long-acting tablets with blue speckles

Dura-Vent, 600 mg of guaifenesin and 75 mg of phenylpropanolamine--white, scored tablets

See also: Coldloc-LA side effects (in more detail)

Thursday, 8 March 2012

Vibra-Tabs

Commonly used brand name(s)

Uses For Vibra-Tabs

Before Using Vibra-Tabs

Allergies

Pediatric

Geriatric

Pregnancy

Breast Feeding

Interactions with Medicines

Interactions with Food/Tobacco/Alcohol

Other Medical Problems

Proper Use of doxycycline

Dosing

Missed Dose

Storage

Precautions While Using Vibra-Tabs

Vibra-Tabs Side Effects

More Vibra-Tabs resources

Compare Vibra-Tabs with other medications

Monday, 5 March 2012

Acular eent

Introduction

Uses for Acular

Conjunctivitis

Postoperative Ocular Inflammation

Postoperative Ocular Pain

Cystoid Macular Edema

Inhibition of Intraoperative Miosis

Acular Dosage and Administration

Administration

Ophthalmic Administration

Dosage

Pediatric Patients

Conjunctivitis

Ophthalmic

Postoperative Ocular Inflammation

Ophthalmic

Postoperative Ocular Pain

Ophthalmic

Adults

Conjunctivitis

Ophthalmic

Postoperative Ocular Inflammation

Ophthalmic

Postoperative Ocular Pain

Ophthalmic

Cystoid Macular Edema

Postoperative Cystoid Macular Edema†

Chronic Aphakic or Pseudophakic Cystoid Macular Edema†

Cautions for Acular

Contraindications

Warnings/Precautions

Warnings

Hematologic Effects

Sensitivity Reactions

Cross-sensitivity

General Precautions

Wound Healing Complications

Ocular Effects

Specific Populations

Pregnancy

Lactation

Pediatric Use

Geriatric Use

Common Adverse Effects

Interactions for Acular

Specific Drugs

Acular Pharmacokinetics

Absorption

Bioavailability

Distribution

Extent

Plasma Protein Binding

Stability

Storage

Ophthalmic

0.4% Solution

0.5% Solution